HB1497, titled the NIH Reform Act, would reorganize the National Institute of Allergy and Infectious Diseases (NIAID) by replacing it with three separate institutes within the National Institutes of Health: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases. The bill amends multiple provisions of the Public Health Service Act to create these new institutes, define their purposes, and transfer existing authorities and functions from NIAID into the new entities.
The bill also changes the leadership structure for these institutes. It terminates the current NIAID director position upon enactment, places the new institutes under the NIH Director temporarily, and requires the President to appoint each new institute director with Senate advice and consent for five-year terms, with one possible reappointment. It further updates statutory references throughout federal law so that any mention of NIAID is treated as a reference to the appropriate successor institute.
In practical terms, the bill would alter federal public health law and the internal organization of NIH rather than create new external programs or benefits. It would split research, training, and information-dissemination responsibilities currently housed in one institute into three separate statutory entities, affecting how federal research on allergies, infectious diseases, tropical diseases, and immunologic disorders is administered and overseen.
Because there are no committee transcripts or recorded votes provided, the available context shows only that the bill was introduced and referred to the House Committee on Energy and Commerce. No formal legislative sentiment can be measured from votes, but the bill’s title and structure suggest it is framed as an NIH restructuring measure. The main point of contention likely concerns whether dividing NIAID would improve specialization and accountability or instead fragment research coordination and disrupt existing NIH operations.
The bill would amend the Public Health Service Act to eliminate the single National Institute of Allergy and Infectious Diseases as a statutory entity and replace it with three new institutes, each with its own defined mission and director. It would also require broad conforming changes across federal law, regulations, and agency documents to redirect references from NIAID to the appropriate successor institute. The measure would therefore reshape NIH governance, leadership appointments, and the statutory allocation of research authority over allergy, infectious disease, and immunology programs.
No committee discussion or vote history is available, so there is no recorded legislative sentiment from debate or roll call. Based on the text alone, the bill appears to be a reform-oriented restructuring proposal aimed at reorganizing NIH research functions. The absence of supporting materials makes it impossible to identify bipartisan support or opposition, but the proposal is likely to draw interest from stakeholders in biomedical research administration, public health, and federal agency oversight.
The central policy question is whether splitting NIAID into three separate institutes would improve focus and accountability or create unnecessary bureaucracy and disrupt integrated research efforts. Supporters would likely argue that allergies, infectious diseases, and immunologic disorders are distinct enough to merit dedicated institutes and leadership. Opponents would likely worry about duplication, administrative costs, transition burdens, and the loss of coordination across closely related research areas, especially for diseases that overlap immunology and infectious disease.